Tatva Chintan Pharma Chem's Q1 FY 2025-26 Quarterly Results

Result Summary

• Tatva Chintan Pharma Chem Ltd reported a 14.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.7%.
• Its expenses for the quarter were up by 22.2% QoQ and 9.1% YoY.
• The net profit decreased 30.8% QoQ and increased 27.6% YoY.
• The earnings per share (EPS) of Tatva Chintan Pharma Chem Ltd stood at 2.8 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Tatva Chintan Pharma Chem Ltd is a company operating in the chemical industry, primarily focusing on the production and supply of specialty chemicals. These chemicals are essential for various applications in industries such as pharmaceuticals, agrochemicals, and personal care. The company's product portfolio includes phase transfer catalysts, structure-directing agents, electrolyte salts for supercapacitor batteries, and pharmaceutical intermediates. Tatva Chintan Pharma Chem Ltd has established a significant presence in both domestic and international markets, catering to a diverse clientele. As of the latest data available up to October 2023, there are no major developments or announcements specific to the company beyond the financial figures provided for the recent quarter.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Tatva Chintan Pharma Chem Ltd reported a total income of ₹118.02 crores. This represents an increase from ₹102.79 crores in the previous quarter (Q4FY25) and ₹106.64 crores in the same quarter of the previous year (Q1FY25). The quarter-over-quarter (QoQ) growth rate for total income is 14.8%, while the year-over-year (YoY) growth rate stands at 10.7%. These figures indicate an upward trend in revenue generation for the company in comparison to both the previous quarter and the corresponding quarter of the previous year.

Profitability

The company's profitability metrics show varying trends in Q1FY26. The profit before tax amounted to ₹9.10 crores, a decrease from ₹13.69 crores in Q4FY25 but an increase from ₹6.81 crores in Q1FY25. This reflects a QoQ decrease of 33.5% and a YoY increase of 33.6%. The tax expense for the latest quarter was ₹2.45 crores, down from ₹4.08 crores in Q4FY25, yet higher than ₹1.60 crores in Q1FY25, indicating a 40.0% QoQ decline and a 53.1% YoY increase. Consequently, the profit after tax for Q1FY26 was ₹6.65 crores, declining from ₹9.61 crores in Q4FY25 but increasing from ₹5.21 crores in Q1FY25. This results in a QoQ decrease of 30.8% and a YoY growth of 27.6%.

Operating Metrics

For the first quarter of fiscal year 2026, Tatva Chintan Pharma Chem Ltd reported total expenses amounting to ₹108.91 crores. This figure marks an increase from ₹89.10 crores in the previous quarter and ₹99.82 crores in the same quarter of the previous year, resulting in a QoQ increase of 22.2% and a YoY increase of 9.1%. The earnings per share (EPS) for Q1FY26 was ₹2.80, down from ₹4.10 in Q4FY25, but up from ₹2.20 in Q1FY25. This reflects a QoQ decrease of 31.7% and a YoY increase of 27.3%. These metrics provide insights into the company's cost structure and shareholder returns during the period in question.